AptarGroup announced the acquisition of Sommaplast, a Brazilian specialist in oral‑dosing pharmaceutical packaging, for $35 million (a price range of $30 million to $35 million). The deal expands Aptar’s footprint in Latin America and adds new product lines—closures, droppers, dispensers and dosing cups—to its Pharma portfolio.
Sommaplast’s expertise in precision injection molding and dosing solutions complements Aptar’s existing capabilities. The acquisition positions Aptar to capture growth in the GLP‑1 and biologics markets, where demand for oral drug delivery systems is accelerating. Aptar’s 25‑year presence in Brazil and its focus on expanding in Latin America make the transaction a natural fit for its long‑term strategy.
Aptar’s Q3 2025 results showed sales up 6% year‑over‑year and an adjusted EBITDA margin of 23.2%, up from 22.9% in the prior year. The Sommaplast acquisition is expected to add incremental revenue and margin expansion in the coming quarters, supporting the company’s earnings outlook for 2025.
Gael Touya, President of Aptar Pharma, said the acquisition will reinforce Aptar’s footprint in Brazil and leverage Sommaplast’s strong commercial capabilities. He emphasized that Aptar will maintain Sommaplast’s family‑owned DNA while integrating it into its global network of solutions and services.
The GLP‑1 market is projected to reach $150 billion by 2032, and biologics are expected to reach $817 billion. Aptar’s Pharma segment, which generates over two‑thirds of group profits, is well positioned to benefit from these trends. The acquisition strengthens Aptar’s ability to serve injectables and oral drug delivery systems.
Aptar anticipates operational synergies from shared manufacturing capabilities and precision injection molding expertise. The integration will enable cross‑selling of Sommaplast’s dosing solutions to Aptar’s existing customers, potentially driving revenue growth and margin improvement.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.